NFKB1 and neoplasm: Our results further demonstrated that co-treatment with lapatinib can sensitize TNBC cells to proteasome inhibitors both in vitro and in vivo (Figure 6), suggesting that the artificial trap of cancer cells to NF-κB signaling by lapatinib may be a potential strategy to increase the anti-tumor activity of bortezomib for TNBC patients.